echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Rigofeni: A New Choice for Neuroblastoma Treatment

    Br J Cancer: Rigofeni: A New Choice for Neuroblastoma Treatment

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Neuroblastoma is the most common type of extracranial solid tumor in children, although there are currently a variety of treatments for the tumor, including chemotherapy, surgical excision, kinetic stem cell transplantation, radiotherapy, drug treatment, but the long-term survival rate of children with high-risk neuroblastoma is less than 40%Previous studies have found that neuroblastoma cells and primary tumors can express a variety of growth factors and receptor kinases that can be used as potential therapeutic targetsHowever, the limited therapeutic effect of therapeutic drugs for single-target or single-signal path suggests that treatment strategies that target multiple related targets at the same time may have better efficacyRegorafenib (BAY73-4506) is a new type of multikinase small molecule inhibitor that has been approved for the treatment of metastatic colorectal cancer, advanced gastrointestinal interstitial melanoma (GIST) and aggressive liver cell carcinomaThe purpose of this study was to evaluate the efficacy of rigofeni in the treatment of neuroblastomaStudies have shown that ragofeny therapy reduces the vitality of neuroblastoma cells, reduces cell fusion, and induces apoptosis and stagnant cell cyclesRigofini therapy inhibits known tyrosine kinase receptor target RET and PDGFR beta, as well as signal transduction within cells, through mediated RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun signaling pathwaysThe researchers then evaluated the inviviability of rgofeni through an in situ transplantoma model and found that rigofeni was effective against neuroblastoma, while the combination of 13-cis-reticacid (13-cis-reictino acid) was more effective than the rigofinu monodrug treatmentThe results of the previous study showed that rigofeni was able to affect a variety of signaling pathways within the cell, and that its combination with 13-shun retinoid acid could provide a better efficacy, providing the basis for the development of rigofeni-related treatment strategies for neuroblastoma
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.